Radiation-delivering microspheres developed by Sirtex are as effective as Nexavar (sorafenib) chemotherapy against a liver cancer known as hepatocellular carcinoma (HCC), according to a Phase 3…
Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…
The latest preclinical results of Ocera Therapeutics’ ammonia scavenger OCR-002 showed that it can reduce fibrosis progression in animal models of non-alcoholic fatty liver…
Galectin Therapeutics’s lead drug GR-MD-02 may be a promising therapeutic approach to treat fibrosis in fatty liver disease — or non-alcoholic steatohepatitis (NASH) — based on results from…
A subset of stem cell-derived immune cells, known as iPS-ML, stopped tumor progression and improved survival of mice with liver cancer, a Japanese study showed.
The transforming growth factor-beta (TGF-beta) protein promotes the conversion of normal liver cells to cancerous cells, a study indicates. It also regulates liver cancer cells’ ability to…
A healthy diet and regular physical exercise were found to influence the levels of circulating fatty acids, a type of lipid molecules, and reduce the…
Researchers from Stony Brook University have described a biochemical mechanism that occurs in the liver and is responsible for the conversion of a lipid…